

# Mohsen Karimi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6676707/publications.pdf>

Version: 2024-02-01

24  
papers

1,631  
citations

430442

18  
h-index

642321

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

3545  
citing authors

#	ARTICLE	IF	CITATIONS
1	A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes. <i>Leukemia</i> , 2020, 34, 271-282.	3.3	13
2	Estimation of flotation rate constant and particle-bubble interactions considering key hydrodynamic parameters and their interrelations. <i>Minerals Engineering</i> , 2019, 141, 105836.	1.8	35
3	Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 522-527.	3.3	7
4	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. <i>Clinical Cancer Research</i> , 2018, 24, 1834-1844.	3.2	136
5	Increased cytomegalovirus replication by 5-Azacytidine and viral-induced cytoplasmic expression of DNMT1 in medulloblastoma and endothelial cells. <i>International Journal of Oncology</i> , 2018, 52, 1317-1327.	1.4	2
6	appreci8: a pipeline for precise variant calling integrating 8 tools. <i>Bioinformatics</i> , 2018, 34, 4205-4212.	1.8	26
7	Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data. <i>Scientific Reports</i> , 2017, 7, 43169.	1.6	185
8	SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. <i>Blood</i> , 2017, 130, 881-890.	0.6	66
9	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. <i>Haematologica</i> , 2017, 102, 498-508.	1.7	34
10	Gene expression and risk of leukemic transformation in myelodysplasia. <i>Blood</i> , 2017, 130, 2642-2653.	0.6	64
11	Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. <i>Cell Reports</i> , 2017, 20, 572-585.	2.9	99
12	Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. <i>Oncotarget</i> , 2016, 7, 72685-72698.	0.8	21
13	Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. <i>Oncotarget</i> , 2016, 7, 22103-22115.	0.8	37
14	Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts. <i>British Journal of Haematology</i> , 2015, 171, 478-490.	1.2	37
15	High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e223-e225.	1.7	12
16	Global changes in DNA methylation in Alzheimer's disease peripheral blood mononuclear cells. <i>Brain, Behavior, and Immunity</i> , 2015, 45, 139-144.	2.0	112
17	Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy. <i>Blood</i> , 2015, 126, 2839-2839.	0.6	0
18	microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2014, 9, 910-917.	1.3	43

#	ARTICLE	IF	CITATIONS
19	Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by <i>DNMT3A</i> mutational status and associated with predominant hypomethylation of HOX genes. <i>Epigenetics</i> , 2014, 9, 1108-1119.	1.3	74
20	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). <i>Haematologica</i> , 2014, 99, 1041-1049.	1.7	116
21	Characterization of the Hematopoietic Stem and Progenitor Cell Hierarchy in Myelodysplastic Syndromes Patients with Monosomy 7 As the Sole Cytogenetic Abnormality. <i>Blood</i> , 2014, 124, 3490-3490.	0.6	16
22	The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. <i>Leukemia</i> , 2013, 27, 889-896.	3.3	89
23	LUMA (Luminometric Methylation Assay) – A high throughput method to the analysis of genomic DNA methylation. <i>Experimental Cell Research</i> , 2006, 312, 1989-1995.	1.2	261
24	Using LUMA: a Luminometric-Based Assay for Global DNA-Methylation. <i>Epigenetics</i> , 2006, 1, 46-49.	1.3	146